peginterferon beta-1a 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
5137 1211327-92-2

Description:

MoleculeDescription

Synonyms:

  • peginterferon beta-1a
  • plegridy
  • BIIB017
an interferon beta-1a to which a single, linear 20,000 dalton methoxy poly(ethyleneglycol)-O-2-methylpropionaldehyde molecule is covalently attached to the alpha amino group of the N-terminal amino acid residue. A possible role for IFNs in prophylaxis or early treatment of COVID-19 has been suggested to compensate for possibly insufficient endogenous IFN production. However, the efficacy and safety of IFNs for treatment or prevention of COVID-19 were not established.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
8.90 mcg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Aug. 15, 2014 FDA BIOGEN IDEC INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Influenza like illness 697.30 24.54 242 5607 80369 90542229
Multiple sclerosis relapse 533.81 24.54 178 5671 52127 90570471
Injection site erythema 390.71 24.54 168 5681 98334 90524264
Injection site reaction 212.04 24.54 108 5741 91972 90530626
Device malfunction 135.64 24.54 51 5798 20926 90601672
Injection site pruritus 89.68 24.54 51 5798 53783 90568815
Injection site bruising 72.49 24.54 44 5805 52263 90570335
Injection site rash 69.35 24.54 33 5816 24140 90598458
Abortion spontaneous 68.63 24.54 43 5806 54013 90568585
Maternal exposure during pregnancy 63.88 24.54 96 5753 359967 90262631
Drug delivery system malfunction 61.99 24.54 15 5834 1366 90621232
Injection site pain 60.70 24.54 65 5784 173634 90448964
Lymphopenia 55.92 24.54 28 5821 22853 90599745
Chills 52.58 24.54 53 5796 131928 90490670
General symptom 51.37 24.54 23 5826 14645 90607953
Injection site swelling 37.49 24.54 31 5818 59808 90562790
Magnetic resonance imaging abnormal 35.96 24.54 12 5837 3474 90619124
Caesarean section 34.72 24.54 19 5830 18558 90604040
Leukopenia 33.93 24.54 37 5812 100673 90521925
Central nervous system lesion 33.70 24.54 16 5833 11630 90610968
Product dose omission issue 33.32 24.54 64 5785 291623 90330975
White blood cell count decreased 33.08 24.54 47 5802 167062 90455536
Off label use 33.06 24.54 15 5834 1102237 89520361
Needle fatigue 32.13 24.54 6 5843 156 90622442
Procedural anxiety 31.86 24.54 8 5841 848 90621750
Anal polyp 28.97 24.54 5 5844 82 90622516
Adverse reaction 28.84 24.54 20 5829 29692 90592906
Balance disorder 28.16 24.54 33 5816 97047 90525551
Injection site urticaria 27.14 24.54 16 5833 17995 90604603
Product administered to patient of inappropriate age 25.36 24.54 10 5839 4643 90617955
Gait disturbance 24.78 24.54 53 5796 260443 90362155

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Influenza like illness 330.23 35.12 87 927 31753 42588568
Multiple sclerosis relapse 186.18 35.12 47 967 14217 42606104
Injection site erythema 86.68 35.12 28 986 20167 42600154
Injection site reaction 80.73 35.12 25 989 15696 42604625
Chills 37.83 35.12 25 989 94041 42526280

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Influenza like illness 649.39 27 214 4714 88198 110496173
Multiple sclerosis relapse 485.19 27 150 4778 50090 110534281
Injection site erythema 371.32 27 144 4784 94032 110490339
Injection site reaction 152.87 27 76 4852 88994 110495377
Device malfunction 100.09 27 39 4889 25519 110558852
Injection site pruritus 88.62 27 44 4884 51214 110533157
Injection site bruising 74.08 27 39 4889 51224 110533147
Chills 74.07 27 64 4864 190516 110393855
Injection site rash 68.54 27 29 4899 23390 110560981
Injection site pain 59.68 27 55 4873 177867 110406504
Abortion spontaneous 57.97 27 29 4899 34253 110550118
Maternal exposure during pregnancy 56.56 27 63 4865 254820 110329551
Drug delivery system malfunction 49.28 27 11 4917 1024 110583347
Lymphopenia 45.42 27 26 4902 40144 110544227
Injection site swelling 35.19 27 26 4902 61764 110522607
Magnetic resonance imaging abnormal 34.69 27 11 4917 3934 110580437
Loss of control of legs 32.06 27 9 4919 2123 110582248
Product administered to patient of inappropriate age 30.51 27 12 4916 8024 110576347
Anal polyp 30.27 27 5 4923 92 110584279
Leukopenia 29.94 27 35 4893 148756 110435615
Product dose omission issue 29.47 27 52 4876 321730 110262641
Paralysis 28.75 27 14 4914 15586 110568785
Balance disorder 27.87 27 30 4898 116530 110467841
Prolonged labour 27.77 27 6 4922 480 110583891
Caesarean section 27.28 27 13 4915 13804 110570567
Injection site alopecia 27.06 27 3 4925 0 110584371

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L03AB13 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSTIMULANTS
IMMUNOSTIMULANTS
Interferons
FDA CS M0025715 Interferon-beta
FDA EPC N0000191625 Interferon beta
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35705 immunosuppressive agent

Related Drugs by ATC class:

L03AB Interferons 6 drugs
interferon alfa-2binterferon beta-1ainterferon beta-1bpeginterferon alfa-2apeginterferon alfa-2bropeginterferon alfa-2b

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Relapsing remitting multiple sclerosis indication 426373005 DOID:2378




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Interferon alpha/beta receptor Membrane receptor AGONIST DRUG LABEL DRUG LABEL

External reference:

IDSource
I8309403R0 UNII
4033770 VANDF
C3848580 UMLSCUI
CHEBI:753625 CHEBI
CHEMBL2108677 ChEMBL_ID
D10483 KEGG_DRUG
DB09122 DRUGBANK_ID
9661 INN_ID
C428112 MESH_SUPPLEMENTAL_RECORD_UI
7637 IUPHAR_LIGAND_ID
1546168 RXNORM
227899 MMSL
30489 MMSL
d08282 MMSL
015648 NDDF
706897007 SNOMEDCT_US
714201001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
PlegridyPen HUMAN PRESCRIPTION DRUG LABEL 1 64406-011 INJECTION, SOLUTION 125 ug SUBCUTANEOUS BLA 27 sections
Plegridy HUMAN PRESCRIPTION DRUG LABEL 1 64406-015 INJECTION, SOLUTION 125 ug SUBCUTANEOUS BLA 27 sections
Plegridy HUMAN PRESCRIPTION DRUG LABEL 1 64406-017 INJECTION, SOLUTION 125 ug INTRAMUSCULAR BLA 27 sections